Baxter Intl Inc Stock Price, News & Analysis

Baxter International Inc. (NYSE:BAX) has completed its acquisition of Hillrom for $10.5 billion, paying $156 per share in cash. This transaction aims to enhance Baxter's healthcare transformation vision and is expected to generate approximately $250 million in annual pre-tax cost synergies by the end of year three. The acquisition is projected to positively impact Baxter's adjusted earnings per share, expanding margins and cash flow generation, with high single-digit returns on invested capital anticipated by year five. The combination will also enhance product accessibility globally.

Baxter International Inc. (NYSE:BAX) announced findings from a study suggesting that machine learning and AI can enhance medication safety in hospitals. Conducted with MedAware, the research analyzed over 3.8 million infusions and found that AI could assist in adjusting Dose Error Reduction Systems (DERS) to reduce medication errors. The results indicated that 52% of outliers triggered hard limits, showcasing the need for better DERS limits. The study was presented at the ASHP 2021 Midyear Clinical Meeting, highlighting advancements in infusion pump technology for patient safety.

Baxter International Inc. (NYSE:BAX) has declared a quarterly cash dividend of $0.28 per share, payable on January 3, 2022, to shareholders recorded as of December 3, 2021. This dividend reflects an annual rate of $1.12 per share. The announcement emphasizes the company's commitment to returning value to its shareholders through consistent dividend payments.

Baxter International Inc. (NYSE:BAX) has announced a significant investment of approximately $100 million to expand its sterile fill/finish manufacturing facility in Halle/Westfalen, Germany. This expansion will enhance production capabilities with a new syringe filling line and increased vial capacity, aimed at improving product stability and shelf life via lyophilization. The construction is set to start in 2022 and be completed by 2024, positioning Baxter to meet rising demand for injectable pharmaceuticals across Europe and the United States.

Baxter International Inc. (NYSE:BAX) presented new findings at the American Society of Nephrology’s Kidney Week, indicating that patients using the Sharesource remote patient management platform for automated peritoneal dialysis (APD) experienced nearly double the survival rates compared to those using conventional methods. This study, involving 815 kidney patients across 22 hospitals in Mexico, suggests that digital health solutions can significantly enhance clinical outcomes, reducing hospital visits during the COVID-19 pandemic.

Baxter International Inc. (NYSE:BAX) will present at the Evercore ISI 4th Annual HealthCONx Conference on Thursday, December 2, 2021. Chief Financial Officer Jay Saccaro is set to speak at 9:40 a.m. Eastern Time. Investors and the public can access the live webcast of the presentation through www.baxter.com, which will also be available for replay until May 21, 2022. Baxter continues to innovate in medical products, impacting patients and healthcare providers globally.

Baxter International reported a 9% increase in third-quarter revenue, reaching $3.2 billion, driven by strong sales across all geographic segments. U.S. GAAP earnings per share rose 29% to $0.89, while adjusted EPS increased by 23% to $1.02. Baxter anticipates full-year sales growth of 7%-8% and adjusted EPS between $3.58 and $3.62. The company announced the acquisition of Hillrom, aiming to enhance its product portfolio and innovation pipeline. Additionally, Baxter launched new medical products and received FDA approval for premix Norepinephrine Bitartrate injection.